Skip to main content
. Author manuscript; available in PMC: 2012 Mar 1.
Published in final edited form as: Exp Hematol. 2010 Dec 17;39(3):384–390. doi: 10.1016/j.exphem.2010.12.003

Figure 2.

Figure 2

The numbers of circulating myeloid progenitors, (A) granulocyte, macrophage [CFU-GM], (B) erythroid [BFU-E], and (C) granulocyte, erythroid, megakaryocyte, macrophage [CFU-GEMM]), in the peripheral blood following AMD3100-mobilization of C57BL/6 and CD26-/- mice as compared to untreated mice. Comparisons of untreated groups to AMD3100-treated groups were done using a two-tailed student t-test assuming equal variance, n=7-10 mice per group. Previously published data (Christopherson et al., Experimental Hematology 31 (2003) 1126-1134.) for G-CSF mobilization demonstrated that CD26-/- mice had poor mobilization after G-CSF treatment as compared to C57BL/6 mice. These data (D, E and F), reproduced with permission from Experimental Hematology, were also presented as the numbers of circulating myeloid progenitors including (D) CFU-GM, (E) BFU-E, and (F) CFU-GEMM.